Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Capitini CM, Fry TJ, Mackall CL.

Am J Immunol. 2009 Jan 1;5(3):65-83.

3.

NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination.

Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM.

J Immunol. 2010 Sep 1;185(5):2808-18. doi: 10.4049/jimmunol.1000844. Epub 2010 Aug 2.

4.

Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O.

Mol Ther. 2002 May;5(5 Pt 1):609-16.

5.

Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.

Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1031-8. doi: 10.1016/j.bbmt.2008.06.016.

6.

Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy.

Dredge K, Marriott JB, Todryk SM, Dalgleish AG.

Cancer Immunol Immunother. 2002 Nov;51(10):521-31. Epub 2002 Sep 20. Review.

PMID:
12384803
7.

Interleukin-2 in the treatment of renal cancer.

Margolin KA.

Semin Oncol. 2000 Apr;27(2):194-203. Review.

PMID:
10768598
8.

Therapeutic gene modified cell based cancer vaccines.

Kozłowska A, Mackiewicz J, Mackiewicz A.

Gene. 2013 Aug 10;525(2):200-7. doi: 10.1016/j.gene.2013.03.056. Epub 2013 Apr 6. Review.

PMID:
23566846
10.
11.

Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18.

Lauwerys BR, Garot N, Renauld JC, Houssiau FA.

J Immunol. 2000 Aug 15;165(4):1847-53.

12.

Evaluation of humoral and cellular immune responses to a DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.

Xiao Z, Juan L, Song Y, Zhijian Z, Jing J, Kun Y, Yuna H, Dongfa D, Lili D, Liuxin T, Fei L, Nan L, Fang Y, Yuying S, Yongzhi X.

Hum Vaccin Immunother. 2015;11(4):938-45. doi: 10.1080/21645515.2015.1010977.

13.

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.

Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd.

Clin Cancer Res. 2007 Nov 1;13(21):6419-28. Epub 2007 Oct 25.

14.

Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.

Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H.

Cancer Res. 2000 Sep 1;60(17):4838-44.

15.

Cytokine regulation of natural killer cell effector functions.

Zwirner NW, Domaica CI.

Biofactors. 2010 Jul-Aug;36(4):274-88. doi: 10.1002/biof.107. Review.

PMID:
20623510
16.

Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.

Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D.

Blood. 2003 Mar 1;101(5):1718-26. Epub 2002 Oct 24.

17.

Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.

Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, Yoshikawa T, Kubota-Koketsu R, Ikuta K, Okamoto S, Mori Y, Kunisawa J, Kiyono H, Itoh N, Nagano K, Kamada H, Tsutsumi Y, Tsunoda S.

J Virol. 2010 Dec;84(24):12703-12. doi: 10.1128/JVI.01182-10. Epub 2010 Sep 29.

18.

Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.

Bodey B, Bodey B Jr, Siegel SE, Kaiser HE.

Anticancer Res. 2000 Jul-Aug;20(4):2665-76. Review.

PMID:
10953341
19.

Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.

Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS.

Exp Hematol. 2009 Oct;37(10):1216-29. doi: 10.1016/j.exphem.2009.07.009. Epub 2009 Jul 26.

PMID:
19638292

Supplemental Content

Support Center